



DOCKET NO. 147243 (CIR 24 AP)

RECEIVED

DEC 3 1 2001

PATENT

TECH CENTER 6000/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Chow et al.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Office of Initial Patent Examination, Customer Service Center, Washington, D.C. 20231 on:

10/25/01

(Date of Deposit)

Bonnie Ferguson

Printed Name of Person Making Deposit

Bonnie Ferguson

Signature

10/25/01

Date of Signature

Serial No.: 09/815,362

Filed: March 21, 2001

For: COMPOUNDS AND METHOD OF
TREATMENT HAVING AGONIST-LIKE ACTIVITY SELECTIVE
AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS
Group Art Unit: 1626

Examiner: Not Yet Assigned

STATEMENT OF STEPHEN A. MUNK

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

I, Stephen A. Munk, am an inventor of the subject matter claimed in the above-referenced patent application.

While at the time the invention was made I was employed by Allergan, Inc., the parent company of the assignee Allergan Sales, Inc., I have not been employed by Allergan for some years. Consequently, I was unaware that this continuing application was filed until after the filing date, and therefore had no opportunity to advise Allergan that the inventor information, including the list of inventors, was incomplete. Thus, the incorrect naming of the inventive entity in this patent application was made without deceptive intent on my part; moreover, it is my understanding that such incorrect indication of inventors was an inadvertent error made when the patent application was filed.

Respectfully submitted,

Dated: 5 October 2001

By: Stephen A. Munk

Stephen A. Munk

DOCKET NO. 17245



RECEIVED

DEC 31 2001

TECH CENTER 1600 PATENT
1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Chow et al.

Serial No.: 09/815,362

Filed: March 21, 2001

For: COMPOUNDS AND METHOD OF
TREATMENT HAVING AGONIST-LIKE ACTIVITY SELECTIVE
AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS
Group Art Unit: 1626

Examiner: Not Yet Assigned

I hereby certify that this correspondence is being
deposited with the United States Postal Service as first
class mail in an envelope addressed to: Assistant
Commissioner for Patents, Office of Initial Patent
Examination, Customer Service Center, Washington,
D.C. 20231 on:

10/25/01

(Date of Deposit)

Bonnie Ferguson
Printed Name of Person Making Deposit

Bonnie Ferguson
Signature

10/25/01

Date of Signature

CONSENT OF ASSIGNEE TO CORRECTION OF INVENTORSHIP

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

As owner of the entire right, title, and interest in the above identified patent application, ALLERGAN hereby consents to the correction of inventorship to add Stephen A. Munk as an inventor in the above-referenced patent application. ALLERGAN'S right to take action pursuant to 37 CFR 3.73 is established in an Assignment from the inventors to ALLERGAN recorded in the Patent and Trademark Office on August 16, 1996 at Reel 8135, Frame 0552.

I, the undersigned, declare that I am authorized to make this appointment on behalf of Allergan Sales, Inc.

Respectfully submitted,



Martin A. Voet
Assistant Secretary
Allergan Sales, Inc.
2525 Dupont Drive
Irvine CA 92612